Axsome Therapeutics, Inc. AXSM
139.61 USD +3.60 (+2.65%)
At closeNov 3, 2026, 4:25 PM EST
139.61 0.00 0.00%
After hours · Nov 3, 4:25 PM ET
136.88 Day range 145.50
123.00 52-week range 260.19
- YTD
- -23.56%
- 1 year
- +2.84%
News
benzinga.com Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249 Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $247 to $249.
benzinga.com UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239 UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $256 to $239.
benzinga.com RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273 RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.
benzinga.com Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250 Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $275 to $250.
globenewswire.com Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today…
benzinga.com Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220 Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.
seekingalpha.com Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade) Axsome Therapeutics (AXSM) is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA approval. AUVELITY's ADA launch is progressing slower than hoped, with incremental…
seekingalpha.com Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
benzinga.com Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
marketbeat.com What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call Axsome Therapeutics NASDAQ: AXSM reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's…
zacks.com Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
zacks.com Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.94 per share a year ago.
benzinga.com Axsome Therapeutics Q3 2026 Earnings Call Transcript Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Axsome Therapeutics Q3 EPS $(0.25) Beats $(0.56) Estimate, Sales $259.691M Beat $249.929M Estimate Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.56) by 55.36 percent. This is a 73.4 percent increase over losses of…
globenewswire.com Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
fool.com Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.
zacks.com Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238 Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
fool.com 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks) Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the…
zacks.com Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
fool.com Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.
zacks.com 4 CNS Drug Stocks Worth Watching This World Mental Health Day AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
benzinga.com RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295 RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.
fool.com Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep…
globenewswire.com Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today…
fool.com Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with…
benzinga.com Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267 Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247 Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
benzinga.com $100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285 Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
- benzinga.com Axsome Therapeutics Highlights Alzheimer’s Agitation Impact In Shared Goals Survey The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disruptedNinety-seven percent of care…
globenewswire.com Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care…
benzinga.com 5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.
defenseworld.net Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction Axsome Therapeutics (NASDAQ: AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in…
defenseworld.net Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference Axsome Therapeutics (NASDAQ: AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th…
marketbeat.com Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in…- benzinga.com Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.
- benzinga.com Axsome Therapeutics Dosed First Patient in SUMMIT Phase 3 Trial of AXS-05 For Smoking Cessation Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been…
- benzinga.com Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a…
benzinga.com If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has…
benzinga.com Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.- benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session